Medical information Clinical review pending

Cytogenetics

Immunohistochemistry Carbonic Anhydrase9 CA9 Test

The Immunohistochemistry Carbonic Anhydrase9 (CA9) Test helps in cancer diagnosis by measuring CA9 protein levels in tumor tissue. It aids oncologists in understanding tumor behavior and guiding treatment decisions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Tumor tissue sample. This can be submitted as a formalin-fixed paraffin-embedded (FFPE) block or a formalin-fixed tissue biopsy.
Results: Confirm with the laboratory before booking. Typical turnaround times are approximately 5 days for FFPE blocks and tissue biopsies, and 7 days for large or complex tissue samples.
Preparation: No specific patient preparation is required for this test, as it is performed on tissue samples obtained during a biopsy or surgery. Ensure the sample is correctly labeled and accompanied by relevant clinical information and the histopathology report.

Test priceKSh 7,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Immunohistochemistry Carbonic Anhydrase9 CA9 Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Diagnosis of certain types of cancer.
✓Assessment of tumor aggressiveness.
✓Guiding treatment decisions for specific cancers.
✓Monitoring response to therapy in some cases.
✓Evaluation of tumor tissue characteristics.

In plain language

What this test helps you understand

This test helps identify the presence and level of CA9 protein in tumor tissue, which can provide information about tumor aggressiveness and potential response to certain therapies. It is used as part of a comprehensive cancer diagnostic workup.

The Immunohistochemistry Carbonic Anhydrase9 (CA9) Test is a specialized diagnostic tool used in cancer detection and management. It employs immunohistochemistry techniques to analyze tumor tissues for the presence of Carbonic Anhydrase 9 (CA9), a protein often found in higher amounts in certain types of cancer. This test provides valuable information about the tumor's characteristics, potentially influencing treatment strategies. Early and accurate diagnosis is crucial for effective cancer treatment, making this test an important resource for healthcare providers and patients. This test measures the levels of CA9 in tumor tissues, offering insights into tumor aggressiveness and potential responses to therapy. High CA9 levels are sometimes associated with specific cancers, such as renal cell carcinoma. Discuss the relevance of this test with your doctor.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo specific patient preparation is required for this test, as it is performed on tissue samples obtained during a biopsy or surgery. Ensure the sample is correctly labeled and accompanied by relevant clinical information and the histopathology report.

SampleTumor tissue sample. This can be submitted as a formalin-fixed paraffin-embedded (FFPE) block or a formalin-fixed tissue biopsy.

MethodologyImmunohistochemistry (IHC) using specific antibodies to detect the CA9 protein in tissue sections.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test detects the presence and level of CA9 protein. Results must be interpreted by a qualified pathologist or oncologist in conjunction with other clinical and pathological findings. The test may not be applicable to all types of cancer.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

Carbonic Anhydrase 9 (CA9) is an enzyme (protein) that is often found in higher levels in certain types of cancer cells compared to normal cells. Its presence can provide information about the tumor.

This test is performed to help diagnose certain cancers, assess how aggressive a tumor might be, and potentially guide treatment decisions based on the presence and level of CA9 in the tumor tissue.

A sample of the tumor tissue is required. This is usually obtained during a biopsy or surgery and can be submitted as a formalin-fixed paraffin-embedded block or a formalin-fixed tissue biopsy.

Turnaround time can vary. Confirm with the laboratory before booking. Typical times are around 5 days for standard samples.

A qualified pathologist or oncologist will interpret the results of the CA9 test, considering the staining pattern and intensity in the context of the patient's overall medical history and other test results.

Insurance coverage varies. Please check with your insurance provider regarding coverage for this specific test.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp